분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-07-27 17:40:05 , Hit : 918
 Lytic and latent viral replication prevented with CRISPR/Cas9

van Diemen FR, Kruse EM, Hooykaas MJG, Bruggeling CE, Schürch AC, van Ham PM, et al. (2016) CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog 12(6): e1005701. doi:10.1371/journal.ppat.1005701



Herpesviruses are large DNA viruses that are carried by almost 100% of the adult human population.  Employing the CRISPR/Cas9 gene editing approach, virologists from the University Medical Center Utrecht have targeted sites in three different herpesviruses Human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) and Herpes simplex virus (HSV) type 1 to inhibit their viral replication.

Viral targeting using multiple gRNAs


Researchers set out to combat both productive and latent herpesvirus infections by exploiting the CRISPR/Cas9 system to target viral genetic elements important for virus fitness.  Published in PLOS Pathogens, they showed effective abrogation of HCMV and HSV-1 replication by targeting gRNAs to essential viral genes.

Simultaneous targeting of HSV-1 with multiple gRNAs completely abolished the production of infectious particles from human cells. Using the same approach, EBV was almost completely cleared from latently infected EBV-transformed human tumor cells.  This demonstrates the possibility of the CRISPR/Cas9 system in the future targeting herpesvirus genomes as part of a potent prophylactic and therapeutic anti-viral strategy that may be used to impair viral replication and clear latent virus infection.


Biorbyt LLC
369 Pine St. Suite 103
San Francisco
94104, California, USA Email: info@biorbyt.com
Website: www.biorbyt.com
Twitter: twitter.com/Biorbyt









987   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1072
986   Nano-CRISPR Packages Attain 90% Delivery Rate with Engineered Cas9  이성욱 2017/02/09 1328
985   유전자 치료로 청력 되살린다  이성욱 2017/02/08 1350
984   바이러스들도 서로 소통..“상황에 따라 감염방식 결정”  이성욱 2017/01/24 1133
983   Oligonucleotide Therapeutics Near Approval  이성욱 2017/01/10 1168
982   Off Switch Found for Common Version of the CRISPR-Cas9 System  이성욱 2017/01/02 994
981   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 820
980   RNA Modification Helps Drosophila Straighten Up and Fly Right  이성욱 2016/12/10 887
979   Anti-CRISPR Protein Is Gene Editing “Off-Switch”  이성욱 2016/12/10 1890
978   Could Gene Therapy Work for Alzheimer’s Disease?  이성욱 2016/10/12 1158
977   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1147
976   DNA Can Be Edited Without Being Cut  이성욱 2016/08/30 1419
975   Using RNA to Amplify RNA  이성욱 2016/08/16 1031
974   CRISPR: No Cutting Required  이성욱 2016/08/06 1637
973   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1038
  Lytic and latent viral replication prevented with CRISPR/Cas9  이성욱 2016/07/27 918
971   Chinese Scientists To Test Gene Modifying Technique ‘CRISPR’ On Humans For The First Time  이성욱 2016/07/27 1095
970   FDA OKs AbbVie's once-daily Viekira XR for HCV-1  이성욱 2016/07/27 908
969   [미국] 유전자가위 규제 마련 지연과 기업들의 움직임  이성욱 2016/07/21 1104
968   5년새 20배 성장 `유전자치료제` 시장..경쟁력 확보 필수  이성욱 2016/07/21 986

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN